INOTREM
23.7.2020 07:02:05 CEST | Business Wire | Press release
Inotrem S.A., a biotechnology company specialized in the development of immunotherapies targeting the TREM-1 pathway, announced today that it has obtained authorization to launch its phase IIa clinical trial in COVID-19 patients in France, Belgium and the USA.
For this study, Inotrem received a non-dilutive funding as part of the call for proposals PSPC Covid, financed by the Investments d’Avenir Program which managed on behalf of the French government by Bpifrance, France’s public investment bank. Inotrem with its partners the CHRU of Nancy and the CHU of Limoges, was one of the 6 French biotech companies who benefited from this programme to support the research and development of therapeutic solutions targeting COVID-19.
The goal of this first exploratory study is to determine the safety and tolerability and potential signals of efficacy of nangibotide in critically ill patients with COVID-19 with features of systemic inflammation. The objective of this project is to have a positive impact on the severity of the respiratory failure, reduce duration of mechanical ventilation, length of stay in ICU and reduce mortality. Sixty patients will be enrolled in Europe and in the United States. This study follows an observational study in 27 patients, conducted by Prof. Sébastien Gibot at the CHRU of Nancy, which showed an increased expression of the TREM-1 pathway in severe COVID-19 patients. TREM-1 is an immunomodulatory receptor expressed on innate immune cells which amplifies and maintains inflammation.
Previous clinical studies with nangibotide demonstrated its safety and tolerability in patients suffering from septic shock, which is also characterized by a systemic inflammatory reaction. Pre-clinical models have shown that nangibotide inhibits the amplification of the immune response caused by the activation of TREM-1 and was able to restore appropriate inflammatory response, vascular function, and improved survival in septic shock models. Inotrem is currently conducting a Phase IIb trial (ASTONISH) to treat septic shock patients with nangibotide in 6 European countries and in the United States. It is also developing, with Roche Diagnostics, a companion diagnostic test to identify septic schock patients more likely to benefit from its nangibotide treatment.
Coronavirus disease 2019 is a new pandemic disease that arises as a consequence of infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). The optimum treatment strategy in the management of critically ill patients with COVID-19 continues to evolve and, in addition to supportive therapies such as mechanical ventilation, vasopressors and renal replacement therapy, may include immunomodulatory approaches, such as nangibotide, in patients with severe disease.
Professor Sébastien Gibot, Nancy University Hospital and coordinating investigator said “We observed that the TREM-1 pathway was activated in severe forms of COVID-19. Nangibotide is a TREM-1 inhibitor and has the potential to restore an appropriate immune response. We are hoping to demonstrate that nangibotide will reduce the duration of hospitalization and mortality of critically ill patients suffering from COVID-19”.
Jean-Jacques Garaud, CEO of Inotrem, declared: “We are very pleased with both the granting of this financial support and the clearance to start our clinical trial. The French administration has been very effective in working in a coordinated and rapid fashion.”
About Inotrem
Inotrem S.A. is a biotechnology company specialized in immunotherapy for acute and chronic inflammatory syndromes. The company has developed a new concept of immunomodulation that targets the TREM-1 pathway to control unbalanced inflammatory responses. Through its proprietary technology platform, Inotrem has developed the first-in-class TREM-1 inhibitor, LR12 (nangibotide), with potential applications in a number of therapeutic indications such as septic shock and myocardial infarction. In parallel, Inotrem has also launched another program to develop a new therapeutic modality targeting chronic inflammatory diseases. The company was founded in 2013 by Dr. Jean-Jacques Garaud, a former head of research and early development at the Roche Group, Prof. Sébastien Gibot and Dr. Marc Derive. Inotrem is supported by leading European and North American investors.
www.inotrem.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20200722005598/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Energy Vault announces the Award of 100 MW / 870 MWh Long-Term Energy Service Agreement to its Development Partner in Australia4.2.2026 15:09:00 CET | Press release
Energy Vault’s development partner in Australia, Bridge Energy, has secured a 14-year Long-Term Energy Service Agreement (LTESA) for the EBOR Battery Energy Storage System (BESS) project (100 MW / 870 MWh), under the NSW Electricity Infrastructure RoadmapEnergy Vault holds the exclusive option to acquire and construct the A$310 million project having supported Bridge through early stage developmentThe project will feature Energy Vault’s proprietary B-VAULT™ technology and Vault-OS™ Energy Management System software to provide essential grid firming capacityEnergy Vault acquired the Stoney Creek 125 MW / 1,000 MWh project in New South Wales in 2025, which also holds an LTESA, as Energy Vault rapidly expands its Australian footprint Energy Vault Holdings, Inc. (NYSE: NRGV) (“Energy Vault”), a leader in sustainable, grid-scale energy storage solutions, and Bridge Energy Pty Ltd (“Bridge Energy”), an Australian developer bridging the gap between fossil fuels and renewable energy, today ann
Ground Investigation for Civil Infrastructure Gets More Robust With Integration of Lab and Field Geotechnical Data4.2.2026 15:00:00 CET | Press release
Major update to leading geotechnical data management solution OpenGround, enables organisations to digitise geotechnical lab testing, enhancing efficiency and collaboration across engineering teams Seequent, The Bentley Subsurface Company, has streamlined laboratory testing in OpenGround, the leading cloud-connected geotechnical data management solution. The new OpenGround Labs capability enables seamless transfer of soil and rock sample data from field collection to laboratory testing and reporting, with results delivered directly to engineers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260204539856/en/ Geotechnical labs can generate Atterberg limits test certificates from raw lab test data in OpenGround. The advancement enables an end-to-end digital engineering-to-lab workflow, enhancing collaboration and improving efficiency between ground investigation and laboratory testing teams. “Trusted Lab testing data is vital
Torq Lands Virgin Atlantic CISO John White to Lead Enterprise Shift to Agentic AI4.2.2026 15:00:00 CET | Press release
After Transforming Virgin Atlantic’s Cyber Defenses From Legacy Systems to the Torq AI SOC Platform, White Now Helps Global CISOs Navigate the Transition to Agentic Security Operations Torq, the established agentic security operations leader, today announced former Virgin Atlantic CISO John White has joined Torq as Field CISO. Following Torq’s $140M Series D, White shifts from the customer side to the Torq leadership team, propelling global enterprise CISOs to modernize their strategies and adopt true Agentic AI. White is a highly respected security executive with more than 20 years of leadership experience. Prior to Virgin Atlantic, he built and transformed security functions for global organizations including ASOS, Liberty Global, AEG Europe, and KPMG, spanning retail, telecommunications, energy, and live entertainment. At Virgin Atlantic, White did not just oversee security, he reinvented it. Leading a multi-year transformation across airline, cargo, and vacation businesses, White d
Boomi’s Market Momentum Accelerates as Enterprises Standardize on Its AI Activation Platform4.2.2026 15:00:00 CET | Press release
Integration and automation leader achieves 50% customer growth in just over three yearsCompany now serves 30,000+ customers worldwide, including more than a quarter of the Fortune 500Boomi powers enterprise-scale AI with 75,000+ agents running in production Boomi™, the leader in AI-driven automation, today announced that the company’s momentum in enterprise integration and agentic AI has reached a defining moment, driven by unmatched scale, independent analyst validation, proven customer outcomes, and ecosystem growth. With more than 30,000 customers worldwide — including over a quarter of the Fortune 500 — Boomi’s continued growth reflects the trust the world’s largest enterprises place in its platform.Today, customers rely on Boomi’s unique runtime architecture for mission-critical operations — including over 75,000 AI agents in production — executing billions of dollars in transactions with enterprise-grade reliability and resilience. This press release features multimedia. View the
Ras Al Khaimah Ruler Awards Sheikh Saud International Prize for Materials Science at IWAM 20264.2.2026 14:09:00 CET | Press release
Prize underscores Emirate’s global commitment to science, innovation and advanced materials research His Highness Sheikh Saud bin Saqr Al Qasimi, UAE Supreme Council Member and Ruler of Ras Al Khaimah, today awarded the Sheikh Saud International Prize for Materials Science during the 17th International Workshop on Advanced Materials (IWAM), one of the world’s leading forums for advanced materials research. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260204274737/en/ HH Sheikh Saud bin Saqr Al Qasimi-keynote speech at IWAM (Photo: AETOSWire) Presented on day two of IWAM, the Prize recognizes exceptional contributions to materials science and its applications in addressing global challenges. The award was conferred upon Professor Omar Yaghi, winner of the 2025 Nobel Prize in Chemistry, in recognition of his transformative work in materials chemistry and his pioneering contributions to clean energy, carbon capture and sustai
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom